Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 55%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines Ltd presents a compelling outlook due to strong market preferences for its leading product, Brukinsa, which is projected to drive sustained long-term growth, with estimated peak sales reaching approximately $7.1 billion. The company's innovative sonrotoclax is seen as a leading BCL2 inhibitor, with expectations of surpassing competitors like venetoclax in efficacy and safety, potentially contributing to an additional $350 million in revenues. Furthermore, BeOne's strategic focus on physician outreach and competitive contracting is anticipated to bolster Brukinsa's growth trajectory, positioning the company for profitable operations and positive free cash flow by 2025, alongside strong year-over-year growth projections exceeding 40%.

Bears say

The outlook for BeOne Medicines Ltd appears negative due to several fundamental concerns. The company faces challenges such as slower-than-expected uptake of its current commercial products, potential failures in additional indications, and pipeline programs, which could significantly impact revenue generation. Additionally, risks related to geopolitical perceptions, high cash burn without guaranteed returns, and a competitive oncology market, particularly for its flagship product BRUKINSA, further complicate its financial prospects.

BeiGene Ltd (ONC) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 55% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 11 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $380.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $380.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.